Risk  	Risk  	 NN	B-NP
stratification  	stratification  	 NN	I-NP
for  	for  	 IN	I-NP
thromboembolism  	thromboembolism  	 NN	I-NP
and  	and  	 CC	O
antithrombotic  	antithrombotic  	 FW	B-NP
prophylaxis  	prophylaxis  	 FW	I-NP
in  	in  	 FW	O
atrial  	atrial  	 FW	B-NP
fibrillation  	fibrillation  	 FW	I-NP
Atrial  	Atrial  	 FW	I-NP
fibrillation  	fibrillation  	 FW	I-NP
( 	( 	 -LRB-	O
AF 	AF 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
significantly  	significantly  	 RB	O
high  	high  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
stroke  	stroke  	 NN	O
and  	and  	 CC	O
systemic  	systemic  	 JJ	B-NP
embolism  	embolism  	 NNS	I-NP
( 	( 	 -LRB-	O
4.5 	4.5 	 CD	O
% 	% 	 NN	O
/ 	/ 	 CD	O
year 	year 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Oral  	Oral  	 JJ	B-NP
anticoagulant  	anticoagulant  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
( 	( 	 -LRB-	O
OAT 	OAT 	 NNP	B-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
warfarin  	warfarin  	 NNS	B-NP
( 	( 	 -LRB-	O
INR  	INR  	 NNP	B-NP
range  	range  	 NN	I-NP
2.0-3.0 	2.0-3.0 	 CD	O
)  	)  	 -RRB-	O
significantly  	significantly  	 RB	O
reduces  	reduces  	 VBZ	O
thromboembolic  	thromboembolic  	 JJ	B-NP
risk 	risk 	 NN	I-NP
,  	,  	 ,	O
whereas  	whereas  	 IN	O
aspirin  	aspirin  	 NN	O
has  	has  	 VBZ	O
poor  	poor  	 JJ	O
efficacy 	efficacy 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
AF 	AF 	 NNP	B-NP
,  	,  	 ,	O
several  	several  	 JJ	O
scoring  	scoring  	 JJ	O
systems 	systems 	 NNS	O
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
the  	the  	 DT	O
CHADS2  	CHADS2  	 NNP	B-NP
and  	and  	 CC	O
CHA2DS2-VASc  	CHA2DS2-VASc  	 CD	O
scores 	scores 	 NNS	O
,  	,  	 ,	O
are  	are  	 VBP	O
currently  	currently  	 RB	O
used  	used  	 VBN	O
to  	to  	 TO	O
stratify  	stratify  	 VB	O
thromboembolic  	thromboembolic  	 JJ	B-NP
risk 	risk 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
CHA2DS2-VASc  	CHA2DS2-VASc  	 JJ	O
score  	score  	 NN	O
stratifies  	stratifies  	 NN	O
patients  	patients  	 NNS	O
at  	at  	 IN	O
intermediate-low  	intermediate-low  	 JJ	B-NP
thromboembolic  	thromboembolic  	 JJ	I-NP
risk  	risk  	 NN	I-NP
more  	more  	 RBR	O
accurately  	accurately  	 RB	O
than  	than  	 IN	O
the  	the  	 DT	O
CHADS2  	CHADS2  	 JJ	B-NP
score 	score 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
recent  	recent  	 JJ	O
European  	European  	 JJ	O
and  	and  	 CC	O
US  	US  	 NNP	O
guidelines  	guidelines  	 NNS	O
on  	on  	 IN	O
AF  	AF  	 NNP	B-NP
have  	have  	 VBP	O
extended  	extended  	 VBN	O
the  	the  	 DT	O
indications  	indications  	 NNS	O
for  	for  	 IN	O
OAT 	OAT 	 NNP	O
,  	,  	 ,	O
which  	which  	 WDT	O
is  	is  	 VBZ	O
recommended  	recommended  	 VBN	O
not  	not  	 RB	O
only  	only  	 RB	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
at  	at  	 IN	O
high  	high  	 JJ	O
risk 	risk 	 NN	O
,  	,  	 ,	O
but  	but  	 CC	O
also  	also  	 RB	O
for  	for  	 IN	O
those  	those  	 DT	O
at  	at  	 IN	O
intermediate  	intermediate  	 JJ	O
risk 	risk 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
CHADS2  	CHADS2  	 CD	B-NP
score  	score  	 CD	I-NP
≥1 	≥1 	 CD	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice  	practice  	 NN	I-NP
underuse  	underuse  	 NN	I-NP
of  	of  	 IN	O
OAT 	OAT 	 NNP	O
,  	,  	 ,	O
suboptimal  	suboptimal  	 JJ	B-NP
quality  	quality  	 NN	I-NP
of  	of  	 IN	I-NP
anticoagulation 	anticoagulation 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
frequent  	frequent  	 JJ	O
discontinuations  	discontinuations  	 NN	B-NP
of  	of  	 IN	O
treatment  	treatment  	 NN	O
are  	are  	 VBP	O
observed 	observed 	 VBN	O
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
great  	great  	 JJ	O
expectation  	expectation  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
new  	new  	 JJ	O
oral  	oral  	 JJ	B-NP
anticoagulants 	anticoagulants 	 NN	I-NP
,  	,  	 ,	O
in  	in  	 IN	O
particular  	particular  	 JJ	O
the  	the  	 DT	O
direct  	direct  	 JJ	O
thrombin  	thrombin  	 FW	B-NP
inhibitor  	inhibitor  	 FW	I-NP
dabigatran  	dabigatran  	 FW	I-NP
etexilate  	etexilate  	 FW	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
factor  	factor  	 NN	B-NP
Xa  	Xa  	 FW	I-NP
inhibitors  	inhibitors  	 FW	I-NP
rivaroxaban  	rivaroxaban  	 FW	I-NP
and  	and  	 CC	O
apixaban 	apixaban 	 NN	B-NP
,  	,  	 ,	O
which  	which  	 WDT	O
are  	are  	 VBP	O
at  	at  	 IN	O
least  	least  	 JJS	O
non-inferior  	non-inferior  	 JJ	B-NP
to  	to  	 TO	O
warfarin  	warfarin  	 VB	O
and  	and  	 CC	O
safer 	safer 	 JJR	O
,  	,  	 ,	O
and  	and  	 CC	O
seem  	seem  	 VBP	O
to  	to  	 TO	O
be  	be  	 VB	O
a  	a  	 DT	O
suitable  	suitable  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
alternative  	alternative  	 NN	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
old  	old  	 JJ	O
warfarin 	warfarin 	 NN	B-NP
.  	.  	 .	O
